CD44posCD49fhiCD133/2hi Defines Xenograft-Initiating Cells in Estrogen Receptor-Negative Breast Cancer

Defining the populations of tumor-initating cells that are present in tumors is a first step in developing therapeutics to target these cells. We show here that both CD44(pos)CD24(neg) and CD44(pos)CD24(pos) cell populations in estrogen receptor (ER) alpha-negative breast tumors are tumorigenic in m...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2010-06, Vol.70 (11), p.4624-4633
Main Authors: MEYER, Matthew J, FLEMING, Jodie M, LIN, Amy F, AMAL HUSSNAIN, S, GINSBURG, Erika, VONDERHAAR, Barbara K
Format: Article
Language:English
Subjects:
AC133 Antigen
Animals
Antigens, CD - metabolism
Antineoplastic agents
Biological and medical sciences
Breast Neoplasms - genetics
Breast Neoplasms - immunology
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Estrogen Receptor alpha - biosynthesis
Glycoproteins - metabolism
Gynecology. Andrology. Obstetrics
Humans
Hyaluronan Receptors - metabolism
Immunophenotyping
Integrin alpha6 - metabolism
Mammary gland diseases
Medical sciences
Mice
Mice, Inbred NOD
Mice, SCID
Neoplasm Transplantation
Peptides - metabolism
Pharmacology. Drug treatments
Receptor, ErbB-2 - metabolism
Transplantation, Heterologous
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Defining the populations of tumor-initating cells that are present in tumors is a first step in developing therapeutics to target these cells. We show here that both CD44(pos)CD24(neg) and CD44(pos)CD24(pos) cell populations in estrogen receptor (ER) alpha-negative breast tumors are tumorigenic in murine xenograft models. We also describe a third population of xenograft-initiating cells (XIC) enriched in CD44(pos)CD49f(hi)CD133/2(hi) cells that display heightened tumorigenicity, self-renewal in vivo, and the capacity to give rise to functional and molecular heterogeneity. Consistent with their capacity for self-renewal, these cells express elevated levels of Sox2, Bmi-1, and/or Nanog and their CpG islands are hypermethylated relative to nontumorigenic cells. These differences in methylome regulation may be responsible for the dramatic functional differences between the two populations. The identification of CD44(pos)CD49f(hi)CD133/2(hi) XIC in ER-negative tumors may lead to expanded understanding of these tumors and ultimately the development of therapeutics designed to specifically target the cells.
ISSN:0008-5472
1538-7445
DOI:10.1158/0008-5472.can-09-3619